Evaluation of a New Generation of PET-CT OMNI

Oncology Clinical Trial

Official title:

Evaluation of the Quality of Images and the Sensitivity of Detection of Sub-Centimeter Lesions of a New Generation of PET-CT OMNI

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05154877
• Other study ID #: 209658964
• Status: Completed
• Start date: May 30, 2022
• Est. completion date: December 18, 2023

Study information

• Verified date: June 2024
• Source: GE Healthcare
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The overarching purpose of the study is to provide supporting evidence to the value proposition of OMNI, that offers global access to an affordable hybrid PET/CT system similar in performance to that of systems utilized by world-class academic centers. Specifically, the study will collect a library of oncology 18FDG PET image data from the OMNI system and evaluate the images as compared to the standard of care PET/CT systems.

This evaluation is being performed as a necessary part of product development in order to obtain user feedback on device performance, user preference, image quality (IQ), workflow, and new device features. This study will also help to inform protocol development in reducing both scan time and radiologic tracer dose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: December 18, 2023
• Est. primary completion date: August 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years old;

2. A clinical indication for Fluorodeoxyglucose (FDG or 18F-FDG) PET/CT examination according to current clinical practice standards;

3. Have = 1 WHO Karnofsky index < 70;

4. Are able to maintain a supine position twice;

5. Are affiliated with a Social Security scheme in France; AND,

6. Are able and willing to provide informed consent for participation in this study, per the EC approved policy.

Exclusion Criteria:

1. Have uncontrolled diabetes;

2. Have a formal contraindication to certain imaging examinations (i.e., significant claustrophobia, or other contraindications as determined by the ordering physician.)

3. Are known to be pregnant or breastfeeding (the investigational site will follow their standard practice of verifying for women of childbearing age; OR,

4. Are known to have any psychological, family, geographic, or sociological condition that does not allow compliance with the medical monitoring and/or the procedures provided for in the study protocol.

Related Conditions & MeSH terms

• Neoplasms
• Oncology

Intervention

Device:
• OMNI PET/CT Scan
The subject will undergo two PET/CT scans: one on the standard of care scanner and one on the OMNI scanner.

Locations

Country	Name	City	State
France	Institut Claudius Regaud	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
GE Healthcare	Institut Claudius Regaud

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation	Completed image evaluation will be completed using a 5 point Likert Scale of the OMNI system in comparison to the SoC systems for the same subjects, including analysis, reading, and scoring utilizing Likert Scaling and preference questions by three (3) qualified Nuclear Medicine Physicians. Likert scale is 1-5, 3,4 & 5 being of diagnostic quality.	through study completion, an average of 1 year
Primary	Lesion Detectability	Three (3) qualified Nuclear Medicine Physicians shall complete a lesion detectability evaluation of the SoC PET/CT scan (as determined in Phase 1) and OMNI PET/CT scan for each lesion identified for each subject.; Each reader will evaluate the reconstructed images by qualitatively evaluating the visibility of the lesions and by measuring the relevant quantitative values of glycolytic activity of each suspicious lesion (contrast, noise, SUV). The variables conventionally used to quantify the glycolytic activity in PET for characterization, prognosis and therapeutic monitoring are as follows: SUV (Standardized Uptake Value): SUVmax, SUVmean, SUVpeak; Metabolically active volume: VMA; Total glycolysis of the lesion: TLG = SUV x VMA The reader shall provide the location information of each identified lesion.	through study completion, an average of 1 year